279 related articles for article (PubMed ID: 25779963)
1. Dysregulation of parkin in the substantia nigra of db/db and high-fat diet mice.
Khang R; Park C; Shin JH
Neuroscience; 2015 May; 294():182-92. PubMed ID: 25779963
[TBL] [Abstract][Full Text] [Related]
2. Detrimental effects of oxidative losses in parkin activity in a model of sporadic Parkinson's disease are attenuated by restoration of PGC1alpha.
Siddiqui A; Rane A; Rajagopalan S; Chinta SJ; Andersen JK
Neurobiol Dis; 2016 Sep; 93():115-20. PubMed ID: 27185595
[TBL] [Abstract][Full Text] [Related]
3. Repression of rRNA transcription by PARIS contributes to Parkinson's disease.
Kang H; Shin JH
Neurobiol Dis; 2015 Jan; 73():220-8. PubMed ID: 25315684
[TBL] [Abstract][Full Text] [Related]
4. PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival.
Lee Y; Stevens DA; Kang SU; Jiang H; Lee YI; Ko HS; Scarffe LA; Umanah GE; Kang H; Ham S; Kam TI; Allen K; Brahmachari S; Kim JW; Neifert S; Yun SP; Fiesel FC; Springer W; Dawson VL; Shin JH; Dawson TM
Cell Rep; 2017 Jan; 18(4):918-932. PubMed ID: 28122242
[TBL] [Abstract][Full Text] [Related]
5. Promotion of mitochondrial biogenesis via the regulation of PARIS and PGC-1α by parkin as a mechanism of neuroprotection by carnosic acid.
Lin CY; Huang YN; Fu RH; Liao YH; Kuo TY; Tsai CW
Phytomedicine; 2021 Jan; 80():153369. PubMed ID: 33070082
[TBL] [Abstract][Full Text] [Related]
6. Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection.
Kang H; Khang R; Ham S; Jeong GR; Kim H; Jo M; Lee BD; Lee YI; Jo A; Park C; Kim H; Seo J; Paek SH; Lee YS; Choi JY; Lee Y; Shin JH
Oncotarget; 2017 Jul; 8(30):48603-48618. PubMed ID: 28611284
[TBL] [Abstract][Full Text] [Related]
7. PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency.
Pirooznia SK; Yuan C; Khan MR; Karuppagounder SS; Wang L; Xiong Y; Kang SU; Lee Y; Dawson VL; Dawson TM
Mol Neurodegener; 2020 Mar; 15(1):17. PubMed ID: 32138754
[TBL] [Abstract][Full Text] [Related]
8. AMP Kinase Activation is Selectively Disrupted in the Ventral Midbrain of Mice Deficient in Parkin or PINK1 Expression.
Hang L; Thundyil J; Goh GWY; Lim KL
Neuromolecular Med; 2019 Mar; 21(1):25-32. PubMed ID: 30411223
[TBL] [Abstract][Full Text] [Related]
9. High Fat Diet Suppresses Peroxisome Proliferator-Activated Receptors and Reduces Dopaminergic Neurons in the Substantia Nigra.
Kao YC; Wei WY; Tsai KJ; Wang LC
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892244
[TBL] [Abstract][Full Text] [Related]
10. Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration.
Stevens DA; Lee Y; Kang HC; Lee BD; Lee YI; Bower A; Jiang H; Kang SU; Andrabi SA; Dawson VL; Shin JH; Dawson TM
Proc Natl Acad Sci U S A; 2015 Sep; 112(37):11696-701. PubMed ID: 26324925
[TBL] [Abstract][Full Text] [Related]
11. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease.
Shin JH; Ko HS; Kang H; Lee Y; Lee YI; Pletinkova O; Troconso JC; Dawson VL; Dawson TM
Cell; 2011 Mar; 144(5):689-702. PubMed ID: 21376232
[TBL] [Abstract][Full Text] [Related]
12. Identification of transketolase as a target of PARIS in substantia nigra.
Kim H; Kang H; Lee Y; Park CH; Jo A; Khang R; Shin JH
Biochem Biophys Res Commun; 2017 Nov; 493(2):1050-1056. PubMed ID: 28939041
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of Parkinson's disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons.
Giguère N; Pacelli C; Saumure C; Bourque MJ; Matheoud D; Levesque D; Slack RS; Park DS; Trudeau LÉ
J Biol Chem; 2018 Jun; 293(25):9580-9593. PubMed ID: 29700116
[TBL] [Abstract][Full Text] [Related]
14. The Absence of Parkin Does Not Promote Dopamine or Mitochondrial Dysfunction in PolgA
Scott L; Karuppagounder SS; Neifert S; Kang BG; Wang H; Dawson VL; Dawson TM
J Neurosci; 2022 Dec; 42(49):9263-9277. PubMed ID: 36280265
[TBL] [Abstract][Full Text] [Related]
15. Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease.
Dutta D; Ali N; Banerjee E; Singh R; Naskar A; Paidi RK; Mohanakumar KP
Mol Neurobiol; 2018 Jan; 55(1):804-821. PubMed ID: 28062948
[TBL] [Abstract][Full Text] [Related]
16. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
17. Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.
Hennis MR; Marvin MA; Taylor CM; Goldberg MS
Neurobiol Dis; 2014 Feb; 62():113-23. PubMed ID: 24075852
[TBL] [Abstract][Full Text] [Related]
18. S-nitrosylated PARIS Leads to the Sequestration of PGC-1α into Insoluble Deposits in Parkinson's Disease Model.
Kim H; Lee JY; Park SJ; Kwag E; Kim J; Shin JH
Cells; 2022 Nov; 11(22):. PubMed ID: 36429110
[TBL] [Abstract][Full Text] [Related]
19. Parkin deficiency accelerates consequences of mitochondrial DNA deletions and Parkinsonism.
Song L; McMackin M; Nguyen A; Cortopassi G
Neurobiol Dis; 2017 Apr; 100():30-38. PubMed ID: 28042097
[TBL] [Abstract][Full Text] [Related]
20. PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease.
Jo A; Lee Y; Kam TI; Kang SU; Neifert S; Karuppagounder SS; Khang R; Kang H; Park H; Chou SC; Oh S; Jiang H; Swing DA; Ham S; Pirooznia S; Umanah GKE; Mao X; Kumar M; Ko HS; Kang HC; Lee BD; Lee YI; Andrabi SA; Park CH; Lee JY; Kim H; Kim H; Kim H; Cho JW; Paek SH; Na CH; Tessarollo L; Dawson VL; Dawson TM; Shin JH
Sci Transl Med; 2021 Jul; 13(604):. PubMed ID: 34321320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
